Search research articles
Contact Us
Filters
Showing results (51-60 of 100) with videos related to
Page
of 10
Sort By:
Plos One
|
April 17, 2015
Accumulation of an endogenous tryptophan-derived metabolite in colorectal and breast cancers
Paolo Puccetti, Francesca Fallarino, Antoine Italiano, et al.
Cancer Genetics
|
March 9, 2022
PTEN alterations in sporadic and BRCA1-associated triple negative breast carcinomas
Natalie Jones, Audrey Gros, Valérie Velasco, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 9, 2012
Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study
Thomas Bachelot, Céline Bourgier, Claire Cropet, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences
|
May 24, 2024
Identification of non-adherence to adjuvant letrozole using a population pharmacokinetics approach in hormone receptor-positive breast cancer patients
Alicja Puszkiel, Florence Dalenc, Naïma Tafzi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 25, 2016
Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence
Jacquie H Chirgwin, Anita Giobbie-Hurder, Alan S Coates, et al.
Critical Reviews in Oncology/Hematology
|
November 2, 2010
Impact of liposomal doxorubicin-based adjuvant chemotherapy on autonomy in women over 70 with hormone-receptor-negative breast carcinoma: A French Geriatric Oncology Group (GERICO) phase II multicentre trial
Etienne G C Brain, Cécile Mertens, Véronique Girre, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 29, 2015
Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial
Otto Metzger Filho, Anita Giobbie-Hurder, Elizabeth Mallon, et al.
JAMA Oncology
|
March 23, 2018
Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: A Clinical Trial
Melanie Royce, Thomas Bachelot, Cristian Villanueva, et al.
JAMA Network Open
|
December 15, 2022
Association of Endocrine Therapy for HR+/ERBB2+ Metastatic Breast Cancer With Survival Outcomes
Marcela Carausu, Matthieu Carton, Véronique Diéras, et al.
Breast Cancer Research and Treatment
|
February 4, 2014
Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences
Andrea Decensi, Zhuoxin Sun, Aliana Guerrieri-Gonzaga, et al.
Page
of 10
Search research articles
Search
Showing results (51-60 of 100) with videos related to
Sort By:
Page
of 10
Plos One
|
April 17, 2015
Accumulation of an endogenous tryptophan-derived metabolite in colorectal and breast cancers
Paolo Puccetti, Francesca Fallarino, Antoine Italiano, et al.
Cancer Genetics
|
March 9, 2022
PTEN alterations in sporadic and BRCA1-associated triple negative breast carcinomas
Natalie Jones, Audrey Gros, Valérie Velasco, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 9, 2012
Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study
Thomas Bachelot, Céline Bourgier, Claire Cropet, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences
|
May 24, 2024
Identification of non-adherence to adjuvant letrozole using a population pharmacokinetics approach in hormone receptor-positive breast cancer patients
Alicja Puszkiel, Florence Dalenc, Naïma Tafzi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 25, 2016
Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence
Jacquie H Chirgwin, Anita Giobbie-Hurder, Alan S Coates, et al.
Critical Reviews in Oncology/Hematology
|
November 2, 2010
Impact of liposomal doxorubicin-based adjuvant chemotherapy on autonomy in women over 70 with hormone-receptor-negative breast carcinoma: A French Geriatric Oncology Group (GERICO) phase II multicentre trial
Etienne G C Brain, Cécile Mertens, Véronique Girre, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 29, 2015
Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial
Otto Metzger Filho, Anita Giobbie-Hurder, Elizabeth Mallon, et al.
JAMA Oncology
|
March 23, 2018
Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: A Clinical Trial
Melanie Royce, Thomas Bachelot, Cristian Villanueva, et al.
JAMA Network Open
|
December 15, 2022
Association of Endocrine Therapy for HR+/ERBB2+ Metastatic Breast Cancer With Survival Outcomes
Marcela Carausu, Matthieu Carton, Véronique Diéras, et al.
Breast Cancer Research and Treatment
|
February 4, 2014
Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences
Andrea Decensi, Zhuoxin Sun, Aliana Guerrieri-Gonzaga, et al.
Page
of 10